CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant

Stanford University99 enrolled

Overview

Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.

Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide \& Cisplatin for Stage IV Breast Cancer \& Limited Prior Treatment

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Breast Cancer

Interventions

high dose chemo then auto hematopoietic cell transplantPROCEDURE

Eligibility

Sex: ALLMin age: 19 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria:- stage IV breast cancer * primary breast cancer does not express CD34+ * adequate organ function * no evidence of active infection Exclusion Criteria:- chemotherapy within 4 weeks * CNS disease

Locations (1)

Stanford University School of Medicine

Stanford, California, United States

Outcomes

Primary Outcomes

Feasibility and safety

Secondary Outcomes

efficiency of mobilization

tumor contamination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.